TCGA-CQ-5334-01A-01R-1686-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.029452055
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.680
- INTERFERON_GAMMA_RESPONSE+0.590
- ALLOGRAFT_REJECTION+0.530
- G2M_CHECKPOINT+0.450
- MITOTIC_SPINDLE+0.450
- ANGIOGENESIS+0.440
- COMPLEMENT+0.420
- IL6_JAK_STAT3_SIGNALING+0.420
- E2F_TARGETS+0.410
- APICAL_JUNCTION+0.360
Top 10 suppressed
- MYC_TARGETS_V2-0.320
- HYPOXIA-0.300
- OXIDATIVE_PHOSPHORYLATION-0.270
- KRAS_SIGNALING_DN-0.210
- PANCREAS_BETA_CELLS-0.190
- P53_PATHWAY-0.180
- TNFA_SIGNALING_VIA_NFKB-0.080
- GLYCOLYSIS-0.070
- UV_RESPONSE_UP-0.070
- FATTY_ACID_METABOLISM-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-34-8454-01A-11R-2326-07 | — | cohortSQ1 | 0.858 |
| 2 | TCGA-39-5030-01A-01R-1443-07 | — | cohortSQ1 | 0.855 |
| 3 | 738B9C39-A73F-4BD5-A8D4-3F75B9E14569 | — | — | 0.820 |
| 4 | BS_J70GK8SM | Supratentorial Ependymoma | — | 0.818 |
| 5 | TCGA-AR-A250-01A-31R-A169-07 | — | C | 0.813 |
| 6 | SRR934737 | — | — | 0.809 |
| 7 | SRR934943 | — | — | 0.797 |
| 8 | TCGA-ZF-AA5H-01A-11R-A39I-07 | — | — | 0.793 |
| 9 | TCGA-44-6779-01A-11R-1858-07 | — | cohortA1 | 0.792 |
| 10 | SRR650191 | — | — | 0.791 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.680 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.590 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.530 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.450 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.440 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.420 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.360 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.330 | Inavolisib | — uncovered |
| PEROXISOME | 0.270 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.240 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.230 | Inavolisib | — uncovered |